Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback